Thyroid Cancer (Oncology) - Drugs In Development, 2021

July 2021 | 1423 pages | ID: T4DCA7D44723EN
Global Markets Direct

Abstracts

Thyroid Cancer (Oncology) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thyroid Cancer - Drugs In Development, 2021, provides an overview of the Thyroid Cancer (Oncology) pipeline landscape.

Thyroid cancer is a cancer that starts in the thyroid gland. Symptoms include lump that can be felt through the skin on neck, difficulty swallowing, pain in neck and throat and swollen lymph nodes in neck. Predisposing factors include female, high levels of radiation and inherited genetic syndromes. Treatment includes surgery and thyroid hormone therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thyroid Cancer - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Thyroid Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thyroid Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Thyroid Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 5, 53, 36, 5, 29, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 7 and 2 molecules, respectively.

Thyroid Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Thyroid Cancer (Oncology).
• The pipeline guide reviews pipeline therapeutics for Thyroid Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Thyroid Cancer (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Thyroid Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Thyroid Cancer (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Thyroid Cancer (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Thyroid Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Thyroid Cancer - Overview
Thyroid Cancer - Therapeutics Development
Thyroid Cancer - Therapeutics Assessment
Thyroid Cancer - Companies Involved in Therapeutics Development
Thyroid Cancer - Drug Profiles
Thyroid Cancer - Dormant Projects
Thyroid Cancer - Discontinued Products
Thyroid Cancer - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Thyroid Cancer, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Thyroid Cancer - Pipeline by ABM Therapeutics Inc, 2021
Thyroid Cancer - Pipeline by Advanced Accelerator Applications SA, 2021
Thyroid Cancer - Pipeline by Advenchen Laboratories LLC, 2021
Thyroid Cancer - Pipeline by AffyImmune Therapeutics Inc, 2021
Thyroid Cancer - Pipeline by Akeso Inc, 2021
Thyroid Cancer - Pipeline by Alphamab Oncology, 2021
Thyroid Cancer - Pipeline by Arch Oncology Inc, 2021
Thyroid Cancer - Pipeline by Aslan Pharmaceuticals Ltd, 2021
Thyroid Cancer - Pipeline by AstraZeneca Plc, 2021
Thyroid Cancer - Pipeline by Bayer AG, 2021
Thyroid Cancer - Pipeline by BeiGene Ltd, 2021
Thyroid Cancer - Pipeline by Beijing Konruns Pharmaceutical Co Ltd, 2021
Thyroid Cancer - Pipeline by Bicara Therapeutics Inc, 2021
Thyroid Cancer - Pipeline by BioMed Valley Discoveries Inc, 2021
Thyroid Cancer - Pipeline by Biovista Inc, 2021
Thyroid Cancer - Pipeline by Blueprint Medicines Corp, 2021
Thyroid Cancer - Pipeline by BNOAT Oncology Inc, 2021
Thyroid Cancer - Pipeline by Boehringer Ingelheim International GmbH, 2021
Thyroid Cancer - Pipeline by Boston Pharmaceuticals Inc, 2021
Thyroid Cancer - Pipeline by BridgeBio Pharma Inc, 2021
Thyroid Cancer - Pipeline by Bristol Myers Squibb Co, 2021
Thyroid Cancer - Pipeline by C4 Therapeutics Inc, 2021
Thyroid Cancer - Pipeline by CAS-Lamvac Biotech Co Ltd, 2021
Thyroid Cancer - Pipeline by Cello Therapeutics Inc, 2021
Thyroid Cancer - Pipeline by Centrose LLC, 2021
Thyroid Cancer - Pipeline by Chengdu Jinrui Foundation Biotechnology Co Ltd, 2021
Thyroid Cancer - Pipeline by Codiak BioSciences Inc, 2021
Thyroid Cancer - Pipeline by CSPC Pharmaceutical Group Ltd, 2021
Thyroid Cancer - Pipeline by CytImmune Sciences Inc, 2021
Thyroid Cancer - Pipeline by Cytocom Inc, 2021
Thyroid Cancer - Pipeline by CytomX Therapeutics Inc, 2021
Thyroid Cancer - Pipeline by Daiichi Sankyo Co Ltd, 2021
Thyroid Cancer - Pipeline by Debiopharm International SA, 2021
Thyroid Cancer - Pipeline by Ecrins Therapeutics SAS, 2021
Thyroid Cancer - Pipeline by Eisai Co Ltd, 2021
Thyroid Cancer - Pipeline by Eli Lilly and Co, 2021
Thyroid Cancer - Pipeline by EnGeneIC Ltd, 2021
Thyroid Cancer - Pipeline by Exelixis Inc, 2021
Thyroid Cancer - Pipeline by F. Hoffmann-La Roche Ltd, 2021
Thyroid Cancer - Pipeline by Faron Pharmaceuticals Oy, 2021
Thyroid Cancer - Pipeline by Genelux Corp, 2021
Thyroid Cancer - Pipeline by Gradalis Inc, 2021
Thyroid Cancer - Pipeline by Helsinn Group, 2021
Thyroid Cancer - Pipeline by Hutchison MediPharma Ltd, 2021
Thyroid Cancer - Pipeline by ImmunityBio Inc, 2021
Thyroid Cancer - Pipeline by ImmunoForge Co Ltd, 2021
Thyroid Cancer - Pipeline by Immunome Inc, 2021
Thyroid Cancer - Pipeline by IngenoVax LLC, 2021
Thyroid Cancer - Pipeline by InnoCare Pharma Ltd, 2021
Thyroid Cancer - Pipeline by Innovative Cellular Therapeutics Co Ltd, 2021
Thyroid Cancer - Pipeline by Intensity Therapeutics Inc, 2021
Thyroid Cancer - Pipeline by Iovance Biotherapeutics Inc, 2021
Thyroid Cancer - Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2021
Thyroid Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
Thyroid Cancer - Pipeline by Jiangsu Vcare PharmaTech Co Ltd, 2021
Thyroid Cancer - Pipeline by Johnson & Johnson, 2021
Thyroid Cancer - Pipeline by Vaccinex Inc, 2021
Thyroid Cancer - Pipeline by Vascular Biogenics Ltd, 2021
Thyroid Cancer - Pipeline by Xiangxue Life Sciences, 2021
Thyroid Cancer - Pipeline by Xspray Pharma AB, 2021
Thyroid Cancer - Pipeline by Xynomic Pharmaceuticals Holdings Inc, 2021
Thyroid Cancer - Dormant Projects, 2021
Thyroid Cancer - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Thyroid Cancer, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021